Alopecia areata
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Mae Alopecia areata i'w weld ar gefn croen y pen. Mewn achosion nodweddiadol, mae'n ymddangos yn sydyn gydag arwyneb hollol llyfn a maint o 2-3 cm.
References
Mae Alopecia areata yn gyflwr lle mae'ch system imiwnedd yn ymosod ar eich ffoliglau gwallt, gan arwain at golli gwallt dros dro heb greithiau. Gall ymddangos fel darnau o golli gwallt neu effeithio ar groen y pen neu'ch corff cyfan, gan effeithio ar tua 2% o bobl ar ryw adeg yn eu bywydau. Ymddengys mai'r prif droseddwr yw chwalfa yn yr amddiffyniad naturiol o amgylch y ffoliglau gwallt.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Mae Alopecia areata yn gyflwr lle mae'r system imiwnedd yn ymosod ar ffoliglau gwallt, gan achosi colli gwallt ar groen pen a rhannau blewog eraill o'r corff. Mae'n effeithio ar tua 2% o bobl ledled y byd. Er y gall ddigwydd ar unrhyw oedran, mae'n fwy cyffredin ymhlith plant nag oedolion (1. 92% vs. 1. 47%) . Mae menywod, yn enwedig y rhai dros 50 oed, yn dueddol o'i brofi'n fwy na gwrywod. Mae chwistrellu corticosteroidau yn uniongyrchol i'r ardaloedd yr effeithiwyd arnynt wedi dangos canlyniadau gwell na'u cymhwyso'n topig.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Credir bod Alopecia areata yn glefyd hunanimiwn sy'n gysylltiedig â system imiwnedd y ffoliglau gwallt. Mae'r mecanwaith gwaelodol yn cynnwys methiant gan y corff i adnabod ei gelloedd ei hun, gyda dinistrio'r ffoligl gwallt wedi'i gyfryngu gan imiwnedd.
○ Triniaeth ― OTC Drugs
Mae rhai pobl ag alopecia areata ysgafn yn gwella o fewn blwyddyn heb driniaeth. Fodd bynnag, mae'r rhan fwyaf o bobl yn cael eu hailadrodd ar safleoedd ar hap ar groen pen.
#Hydrocortisone cream
○ Triniaeth
Pigiadau steroid intralesional yw'r driniaeth fwyaf effeithiol. Gellir rhoi cynnig ar imiwnotherapi os effeithir ar rannau helaeth o groen y pen.
#Triamcinolone intralesional injection
#DPCP immunotherapy